ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Genentech has struck research partnerships with three biotech companies. The first is with Sosei Heptares to develop small molecules that target G protein–coupled receptors. Sosei could receive up to $26 million in near-term payments and over $1 billion in milestones. The second is with Skyhawk Therapeutics to develop small molecules that alter RNA splicing in cancer and neurodegenerative diseases. Skyhawk could earn more than $2 billion in payments. The third deal is with Convelo Therapeutics to discover drugs that regenerate myelin in the nervous system to treat diseases like multiple sclerosis. Terms were not disclosed.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X